Get the Stockscreener App
0.7127
1.91%
0.0134
Unity Biotechnology Inc stock is traded at $0.7127, with a volume of 21,477.
It is up +1.91% in the last 24 hours and down -36.37% over the past month.
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone which is produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.
See More
Previous Close:
$0.6993
Open:
$0.71
24h Volume:
21,477
Relative Volume:
0.13
Market Cap:
$12.22M
Revenue:
-
Net Income/Loss:
$-52.53M
P/E Ratio:
-0.1947
EPS:
-3.66
Net Cash Flow:
$-39.93M
1W Performance:
-8.52%
1M Performance:
-36.37%
6M Performance:
-42.06%
1Y Performance:
-54.02%
1-Day Range:
$0.7001
$0.7198
1-Week Range:
$0.66
$0.7957
52-Week Range:
$0.66
$3.10
Unity Biotechnology Inc Stock (UBX) Company Profile
Name
Unity Biotechnology Inc
Sector
Industry
Phone
(650) 416-1192
Address
285 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA
Compare UBX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UBX
Unity Biotechnology Inc
|
0.7103 | 12.70M | 0 | -52.53M | -39.93M | -3.66 |
|
ONC
Beone Medicines Ltd Adr
|
245.06 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.65 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.40 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
83.11 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
501.32 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Unity Biotechnology Inc Stock (UBX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-27-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-16-25 | Downgrade | Mizuho | Outperform → Neutral |
| Aug-22-24 | Initiated | Rodman & Renshaw | Buy |
| Nov-16-23 | Upgrade | Wedbush | Neutral → Outperform |
| Jan-04-22 | Upgrade | ROTH Capital | Neutral → Buy |
| Nov-10-21 | Upgrade | Mizuho | Neutral → Buy |
| Jun-28-21 | Upgrade | Citigroup | Sell → Buy |
| Jun-07-21 | Initiated | H.C. Wainwright | Buy |
| Feb-16-21 | Downgrade | Citigroup | Neutral → Sell |
| Aug-18-20 | Downgrade | Citigroup | Buy → Neutral |
| Aug-18-20 | Downgrade | Mizuho | Buy → Neutral |
| Aug-18-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-17-20 | Downgrade | ROTH Capital | Buy → Neutral |
| Jul-28-20 | Initiated | ROTH Capital | Buy |
| Dec-12-19 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-07-19 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-07-18 | Initiated | Mizuho | Buy |
| May-29-18 | Initiated | Citigroup | Buy |
| May-29-18 | Initiated | Goldman | Neutral |
| May-29-18 | Initiated | Morgan Stanley | Overweight |
View All
Unity Biotechnology Inc Stock (UBX) Latest News
HC Wainwright Issues Optimistic Forecast for UBX Earnings - Defense World
Unity Biotechnology stock hits 52-week low at $0.66 - Investing.com
Unity Biotechnology stock hits 52-week low at $0.66 By Investing.com - Investing.com India
Fierce Biotech Layoff Tracker 2025: Keros cuts 70 jobs; iTeos winds down - Fierce Biotech
HC Wainwright & Co. Downgrades Unity Biotechnology (LSE:0YC0) - Nasdaq
Unity Biotechnology (NASDAQ:UBX) Receives Neutral Rating from HC Wainwright - Defense World
Unity Biotech stock rating downgraded at H.C. Wainwright By Investing.com - Investing.com Nigeria
This United States Steel Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday - Benzinga
Unity Biotechnology (UBX) Downgraded Amid Strategic Shifts | UBX Stock News - GuruFocus
HC Wainwright Downgrades Unity Biotechnology to Neutral From Buy, Adjusts Price Target to $2 From $4 - marketscreener.com
Unity Biotechnology (UBX) Downgrade: HC Wainwright & Co. Cuts Pr - GuruFocus
Unity Biotechnology (UBX) Downgrade: HC Wainwright & Co. Cuts Price Target | UBX Stock News - GuruFocus
Biotech company once valued at $700 million slashes entire workforce - MSN
Unity Biotechnology (NASDAQ:UBX) Rating Lowered to “Neutral” at Mizuho - Defense World
Mizuho cuts Unity Biotech stock rating, slashes price target to $1 - Investing.com Nigeria
Mizuho Downgrades Unity Biotechnology to Neutral From Outperform After Diabetic Edema Treatment Misses Primary Endpoint, Cuts Price Target to $1 From $6 - marketscreener.com
Unity Biotechnology (UBX) Downgraded Amid Trials and Strategic N - GuruFocus
Unity Biotechnology (UBX) to Release Earnings on Tuesday - Defense World
Bay Area biotech company Unity, once worth $700M, lays off entire remaining workforce - MSN
'It's a mess out there': More biotech layoffs mean stiff competition for jobs at emerging companies - The Business Journals
Renaissance Technologies LLC Sells 16,759 Shares of Unity Biotechnology, Inc. (NASDAQ:UBX) - Defense World
Bluebird pleads for deal support; Unity, Mersana lay off staff - BioPharma Dive
Bay Area biotech company lays off every single worker, including CEO - SFGATE
Finance Watch: Unity Lays Off All Employees As It Evaluates Alternatives - insights.citeline.com
UNITY Biotechnology (UBX) Reports Promising 36-Week Results from ASPIRE Trial | UBX Stock News - GuruFocus
Unity Biotechnology Explores Strategic Alternatives Post-ASPIRE Study - TipRanks
UNITY Biotechnology Estimates $3.7 Million Expenses For Reduction In Force - marketscreener.com
UNITY Biotechnology Announces Complete 36-Week Results from the ASPIRE Phase 2b Study of UBX1325 in Diabetic Macular Edema and Provides Corporate Updates - The Manila Times
UNITY Biotechnology Announces Complete 36-Week Results from - GlobeNewswire
UNITY Biotechnology Announces Complete 36-Week Results from the ASPIRE Phase 2b Study of - Bluefield Daily Telegraph
UNITY's New DME Treatment Rivals Aflibercept in Phase 2b Trial, Company Explores Strategic Options - Stock Titan
UNITY Biotechnology to Present 36-Week Data from ASPIRE Phase 2B Study at ARVO 2025 Annual Meeting - Nasdaq
UNITY Biotechnology to Present at the ARVO 2025 Annual Meeting - The Manila Times
UNITY Biotechnology tanks after failing to meet goal in eye disorder treatment trial - MSN
Chardan Capital Brokers Decrease Earnings Estimates for UBX - Defense World
Form 8-KCurrent report - ADVFN
HC Wainwright Issues Positive Outlook for UBX Earnings - Defense World
HC Wainwright Reiterates “Buy” Rating for Unity Biotechnology (NASDAQ:UBX) - Defense World
Chardan Capital Reaffirms “Buy” Rating for Unity Biotechnology (NASDAQ:UBX) - Defense World
Unity Biotechnology Reports Q1 2025 Financials and Study Updates - TipRanks
H.C. Wainwright maintains $4 target on Unity Biotech stock - Investing.com Australia
Unity Biotechnology (UBX) Reports $16.9M in Cash, Prepares for F - GuruFocus
H.C. Wainwright maintains $4 target on Unity Biotech stock By Investing.com - Investing.com Nigeria
UNITY Biotechnology (UBX) Shows Promise with Senolytic UBX1325 i - GuruFocus
UNITY Biotechnology Announces Publication in NEJM Evidence - GlobeNewswire
Revolutionary DME Drug Maintains Vision Improvement for 12 Months After Just One Dose, NEJM Study Shows - Stock Titan
UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial R - GuruFocus
Unity Biotechnology Inc Stock (UBX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.76%
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):